Myrtle Potter has served as Chairman of our board of directors since August 2018. Ms. Potter has served as Vant Operating Chair of Roivant Pharma, a business unit of Roivant Sciences, since July 2018. She founded Myrtle Potter & Company, LLC, a private life sciences advisory firm, in September 2005 and served as the CEO until June 2018. Ms. Potter previously served as Chief Operating Officer, and later, President of Genentech, Inc. during a pivotal period of the company’s growth. Under her leadership, Genentech achieved record sales and earnings growth each year. During this time, she was Co-Chair of the company’s Product Portfolio Committee that prioritized and made all investment decisions for Genentech’s clinical development portfolio. Prior to Genentech, Potter was President of Bristol-Myers Squibb’s U.S. Cardiovascular and Metabolic business. Earlier she served at Merck Corporation where she founded and launched the company Astra/Merck, Inc. that was later acquired by Astra AB. Ms. Potter is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the boards of Liberty Mutual Holding Company and Rite Aid Corporation, and previously served on the boards of Amazon, Medco Health Solutions, Inc., Express Scripts Holding Co., subsequent to its acquisition of Medco Health Solutions, Everyday Health, Inc, until its acquisition, as well as other public and privately held companies.
Keith A. Katkin has served as our Principal Executive Officer since May 2018, a member of our board of directors since July 2018, and as the President and Chief Executive Officer of Urovant Sciences Inc. (USI) since September 2017. From March 2007 through January 2016, he was President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where he led the company through its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. He also served as a member of the board of directors of Avanir from 2007 to 2016. Mr. Katkin joined Avanir in July 2005 as the Senior Vice President of Sales and Marketing and a member of Avanir’s executive management team. From 2004 to 2005, Mr. Katkin served as the Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc., a biopharmaceutical company, until it was acquired by Ortho-McNeil Pharmaceutical, Inc., a subsidiary of Johnson and Johnson. Additionally, Mr. Katkin’s employment experience includes leadership roles at InterMune, Inc., Amgen Inc. and Abbott Laboratories. Mr. Katkin currently serves as the chairman of the board of directors of Novus Therapeutics, Inc., and as a director of Syndax Pharmaceuticals Inc. and Rigel Pharmaceuticals, Inc., all of which are publicly traded biopharmaceutical companies. Mr. Katkin earned a B.S. in Business and Accounting from Indiana University and an M.B.A. from the Anderson School at University of California, Los Angeles.
Sef P. Kurstjens, M.D., Ph.D. has served as a member of our board of directors since July 2018. Dr Kurstjens most recently served as Chief Medical Officer at Astellas from April 2013 to April 2018. At Astellas, Dr. Kurstjens was responsible for development, regulatory affairs, medical affairs, pharmacovigilance and quality assurance and was a member of the Corporate Executive Committee. From 2010 to 2013, Dr. Kurstjens was the President and Chief Executive Officer at Agensys, Inc., an early stage oncology Astellas affiliate. Previously, from 2007 to 2010, Dr. Kurstjens served as the Senior Vice President, Chief Medical Officer and Head, Global Drug Development at Allergan. Dr. Kurstjens entered the pharmaceutical industry with Sandoz Pharmaceuticals (now a Novartis International AG company) in Basel, Switzerland in 1991, and from 1993 to 2005 held positions of increasing responsibility with Pfizer Inc. in both Europe and the United States, including VP Worldwide Therapeutic Area Head of Gastrointestinal and Genitourinary. Dr. Kurstjens received his qualifications in medicine and physiology from University of the Witwatersrand in Johannesburg, South Africa.
Pierre Legault has served as a member of our board of directors since July 2018. Mr. Legault has served on the board of directors of Poxel SA since January 2016 and has been Chairman of the board since March 2016. Since February 2018, Mr. Legault has also served on the board of directors and as Chairman of the board for Artios Pharma Limited. Mr. Legault is also a director of Clementia Pharmaceuticals Inc. and Syndax Pharmaceuticals Inc. since January 2018 and January 2017, respectively. Mr. Legault has also previously served as a member of the boards of directors at Forest Laboratories, Tobira Therapeutics, Inc., NPS Pharmaceuticals, Inc., Regado Biosciences, Inc., ARMO Biosciences, Iroko Pharmaceuticals LLC, Cyclacel Pharmaceuticals Inc., Eckerd Pharmacy and NephroGenex, Inc., where he also served as the Chairman and Chief Executive Officer from 2012 to 2016. From 2010 to 2012, Mr. Legault served as the Chief Executive Officer of Prosidion Ltd., a subsidiary of Astellas, and from 2009 to 2010, he served as the Chief Financial Officer and Treasurer of OSI Pharmaceuticals, Inc. Mr. Legault also previously served as the Chief Executive Officer of Eckerd Pharmacy and Senior Executive Vice President and Chief Accounting Officer of the Rite Aid Corporation. Between 1989 and 2005, Mr. Legault held various global roles such as President, Chief Executive Officer and Chief Financial Officer at legacy companies of the Sanofi group. Mr. Legault earned a B.B.A. in Business & International Finance from HEC Montreal, an M.B.A. in Marketing from McGill University and holds C.A. and C.P.A. diplomas. He also studied at Harvard Business School in its Graduate Executive MBA program.
Jim Robinson has served as a member of our board of directors since March 2019. Mr. Robinson has more than 27 years of commercial and operations experience in the biopharmaceutical industry, specifically in the urology, oncology, cardiovascular, infectious disease, hepatitis and CNS markets. Since April 2019, he has held the position of President and Chief Operating Officer at Paragon Biosciences, where he oversees Paragon’s business units and operations. Previously, Mr. Robinson was the President and Chief Operating Officer of Alkermes, where he was responsible for the global commercial, new product planning, corporate planning, manufacturing, quality, human resource and business development functions. Prior to Alkermes, Mr. Robinson spent over 13 years at Astellas US – most recently as President, Americas Operations, from April 2016 through February 2018, where his responsibilities included all aspects of commercial, corporate development, human resources, finance, corporate affairs, compliance, legal and international operations for North and South America. Prior to his role as President of Americas Operations, Mr. Robinson was President, Astellas Pharma US, from April 2013 through March 2016, where he was responsible for leading the US commercial organization. Prior to Astellas, Mr. Robinson spent 13 years at Schering-Plough Pharmaceuticals where his last role was Vice President, Hepatitis Sales and Managed Care. Mr. Robinson serves on the Board of Directors for Neos Therapeutics. He is a founding member and serves on the Board of Directors of MATTER and is also on the Board of Directors for the Chicago Botanic Garden. He received his Bachelor of Science degree from DePaul University.